Greenstein J - Search Results

1

Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis.

Buckle G, Bandari D, Greenstein J, Gudesblatt M, Khatri B, Kita M, Repovic P, Riser E, Weinstock-Guttman B, Thrower B, Loring S, Riester K, Everage N, Prada C, Koulinska I, Mann M. Buckle G, et al. Among authors: greenstein j. Mult Scler J Exp Transl Clin. 2020 Apr 29;6(2):2055217320918619. doi: 10.1177/2055217320918619. eCollection 2020 Apr-Jun. Mult Scler J Exp Transl Clin. 2020. PMID: 32440353 Free PMC article.

2

Diffuse dermatophytosis occurring on dimethyl fumarate therapy.

Greenstein JI. Greenstein JI. Mult Scler. 2018 Jun;24(7):999-1001. doi: 10.1177/1352458517741207. Epub 2018 Apr 13. Mult Scler. 2018. PMID: 29649923

3

Current concepts of the cellular and molecular pathophysiology of multiple sclerosis.

Greenstein JI. Greenstein JI. Dev Neurobiol. 2007 Aug;67(9):1248-65. doi: 10.1002/dneu.20387. Dev Neurobiol. 2007. PMID: 17514718 Review.

4

Heptamer Peptide Disassembles Native Amyloid in Human Plasma Through Heat Shock Protein 70.

Cunningham TJ, Greenstein J, Yao L, Fischer I, Connors T. Cunningham TJ, et al. Among authors: greenstein j. Rejuvenation Res. 2018 Dec;21(6):527-534. doi: 10.1089/rej.2017.2049. Epub 2018 May 30. Rejuvenation Res. 2018. PMID: 29651925 Free PMC article.

5

Anti-inflammatory peptide regulates the supply of heat shock protein 70 monomers: implications for aging and age-related disease.

Cunningham TJ, Greenstein JI, Loewenstern J, Degermentzidis E, Yao L. Cunningham TJ, et al. Among authors: greenstein ji. Rejuvenation Res. 2015 Apr;18(2):136-44. doi: 10.1089/rej.2014.1620. Rejuvenation Res. 2015. PMID: 25485461 Free PMC article.

6

Secreted phospholipase A2 activity in experimental autoimmune encephalomyelitis and multiple sclerosis.

Cunningham TJ, Yao L, Oetinger M, Cort L, Blankenhorn EP, Greenstein JI. Cunningham TJ, et al. Among authors: greenstein ji. J Neuroinflammation. 2006 Sep 11;3:26. doi: 10.1186/1742-2094-3-26. J Neuroinflammation. 2006. PMID: 16965627 Free PMC article.

7

Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up.

Knobler RL, Greenstein JI, Johnson KP, Lublin FD, Panitch HS, Conway K, Grant-Gorsen SV, Muldoon J, Marcus SG, Wallenberg JC, et al. Knobler RL, et al. Among authors: greenstein ji. J Interferon Res. 1993 Oct;13(5):333-40. doi: 10.1089/jir.1993.13.333. J Interferon Res. 1993. PMID: 8301153 Clinical Trial.

8

Systemic recombinant alpha-2 interferon therapy in relapsing multiple sclerosis.

Camenga DL, Johnson KP, Alter M, Engelhardt CD, Fishman PS, Greenstein JI, Haley AS, Hirsch RL, Kleiner JE, Kofie VY, et al. Camenga DL, et al. Among authors: greenstein ji. Arch Neurol. 1986 Dec;43(12):1239-46. doi: 10.1001/archneur.1986.00520120023011. Arch Neurol. 1986. PMID: 3535752 Clinical Trial.

9

Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group.

Smith C, Birnbaum G, Carter JL, Greenstein J, Lublin FD. Smith C, et al. Among authors: greenstein j. Neurology. 1994 Nov;44(11 Suppl 9):S34-42; discussion S42-3. Neurology. 1994. PMID: 7970009 Clinical Trial.

10

Alpha interferon clinical trial for multiple sclerosis: design considerations.

Alter M, Greenstein J, Camenga D, LaRue L. Alter M, et al. Among authors: greenstein j. Neuroepidemiology. 1987;6(1-2):85-92. doi: 10.1159/000110102. Neuroepidemiology. 1987. PMID: 3306431 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

460 results

Search Page